Home  »  Science   »  Aquestive Therapeutics Inc. (NASDAQ: AQST) Could B...

Aquestive Therapeutics Inc. (NASDAQ: AQST) Could Bring Massive Returns?

In the last trading session, 1.02 million shares of the Aquestive Therapeutics Inc. (NASDAQ:AQST) were traded, and its beta was 2.67. Most recently the company’s share price was $2.38, and it changed around -$0.03 or -1.24% from the last close, which brings the market valuation of the company to $123.28M. AQST currently trades at a discount to its 52-week high of $2.65, offering almost -11.34% off that amount. The share price’s 52-week low was $0.62, which indicates that the current value has risen by an impressive 73.95% since then. We note from Aquestive Therapeutics Inc.’s average daily trading volume that its 10-day average is 1.12 million shares, with the 3-month average coming to 507.44K.

Aquestive Therapeutics Inc. (NASDAQ:AQST) trade information

Instantly AQST has showed a red trend with a performance of -1.24% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.69 on Tuesday, 05/23/23 increased the stock’s daily price by 11.52%. The company’s shares are currently up 163.83% year-to-date, but still up 13.33% over the last five days. On the other hand, Aquestive Therapeutics Inc. (NASDAQ:AQST) is 75.00% up in the 30-day period. We can see from the shorts that 1.84 million shares have been sold at a short interest cover period of 6.31 day(s).

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


The consensus price target as assigned by Wall Street analysts is $6.08, which translates to bulls needing to increase their stock price by 60.86% from its current value. Analyst projections state that AQST is forecast to be at a low of $3.00 and a high of $9.50. In order for the stock price to hit the forecast high, the stock would need to plunge -299.16% from its current level, while the stock would need to crash -26.05% from its current level to reach the projected low.

Aquestive Therapeutics Inc. (AQST) estimates and forecasts

Aquestive Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 141.09 percent over the past six months and at a 61.61% annual growth rate that is well above the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will gain 72.20% in revenue this quarter, and will report an increase of 39.10% in the next quarter. The year-over-year growth rate is expected to be -8.80%, down from the previous year.

Consensus estimates provided by 5 financial analysts predict the company will bring in an average of $11.06 million in revenue for the current quarter. 5 analysts expect Aquestive Therapeutics Inc. to make $10.5 million in revenue for the quarter ending Sep 2023. The company’s sales for the same quarters a year ago were $13.27 million and $11.04 million respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -16.60%. Forecasts for the next quarter put sales growth at -4.90%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -19.10%.

AQST Dividends

Aquestive Therapeutics Inc.’s next quarterly earnings report is expected to be released around July 31 and August 04.

Aquestive Therapeutics Inc. (NASDAQ:AQST)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 2.35% of Aquestive Therapeutics Inc. shares, and 26.86% of them are in the hands of institutional investors. The stock currently has a share float of 27.50%. Aquestive Therapeutics Inc. stock is held by 45 institutions, with Bratton Capital Management, LP being the largest institutional investor. By Mar 30, 2023, it held 17.54% of the shares, which is about 9.81 million shares worth $11.18 million.

Vanguard Group, Inc. (The), with 2.34% or 1.31 million shares worth $1.49 million as of Mar 30, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 30, 2022. The former held 0.75 million shares worth $0.68 million, making up 1.35% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 0.41 million shares worth around $0.37 million, which represents about 0.73% of the total shares outstanding.

On Key

Related Posts